← BackCONMED Corp · Electromedical & Electrotherapeutic ApparatusCNMD
Low riskNext report: In 7 days (est.)
The short versionA profitable company with steady sales.
Going well
- Profitable
- Brings in more cash than it spends
- Pays a 1.3% dividend yield
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 0.4% to their holdings in the quarter ending June 2026 (125 bought, 112 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$47.73-2.9% that day
- Company value
- $1.4B
- Share price times all shares
- Price vs profit (P/E)
- 22.8x
- You pay about $23 for each $1 of yearly profit
- Price vs sales
- 1.0x
- Company value is 1.0 times a year of sales
- Dividend yield
- 1.3%
- Yearly dividend as a share of today's price
- Cash vs value
- 3%
- Cash as a share of company value
- Debt vs value
- 58%
- Debt as a share of company value
From CNMD's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$343.5M+6.9% vs a year earlier
Jun '23Tap a barJun '26
Last 12 months: $1.4B, up 6.2% from the 12 months before. Over 5 years, sales grew about 9.8% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.4.7%
- MissDebt under half of equityNot relying on borrowed money.0.81x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.3.4%
- MissProfitable every yearSteady profits, not one good year.9 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$150.9M
- MissShare count not growingNot diluting owners. Falling means buybacks.+3.7% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.54.6%
- Revenue
- $1.4B
- +5.2% vs prior year
- 5-year growth
- +9.8%/yr
- revenue, per year
- Total debt
- $834.2M
- 0.81x equity
- Current ratio
- 2.14x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $343.5M
- +0.3% YoY
- EPS
- $0.77
- vs $0.69
- Op. margin
- 10.6%
- -0.5 pts
- Gross margin
- 57.5%
- +2.5 pts
- Share count
- -3.0%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.2
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+0.4%Institutions added 0.4% to their holdings. 125 bought, 112 sold.
Shares held by institutions34.1M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-0.9%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.6x · $657.0M debtShares outstandingLatest reported
30MNext reportIn 7 days (est.)Estimated from the same quarter last year
- Results filedJul 29
- Results filedApr 29
- Results filedJan 28
- Results filedNov 5, 2025
- Results filedJul 30, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.